Objective: This study evaluated a novel diabetes treatment device that combines commercially available continuous glucose monitoring and insulin infusion technology in such a way as to perform insulin delivery and glucose sensing through a single skin insertion site (singleport device). Methods: Ten type 1 diabetes patients used the device for up to six days in their home/work environment for open-loop insulin delivery and glucose sensing. On an additional day, the device was used in combination with an algorithm to perform automated closed-loop glucose control under hospital settings. To assess the performance of the device, capillary blood glucose concentrations were frequently determined and a continuous glucose sensor was additionally worn by the patients. Results: The average mean absolute relative deviation from blood glucose concentrations obtained for the sensor of the device was low (median, 13.0%; interquartile range, 10.5-16.7%; n = 10) and did not differ from that of the additionally worn glucose sensor (versus 13.9%; 11.9-15.3%; P = 0.922). Furthermore, insulin delivery with the single-port device was reliable and safe during home use and, when performed in combination with the control algorithm, was adequate to achieve and maintain near normoglycemia. Conclusion: Our data show the feasibility of open-and closed-loop glucose control in diabetes patients using a device that combines insulin delivery and glucose sensing at a single tissue site. Significance: The reduction in device size and invasiveness achieved by Manuscript 
I. INTRODUCTION
O VER the past 50 years, a great deal of effort has been devoted to the development of a closed-loop insulin delivery system, or artificial pancreas (AP), that is suitable to automatically control the blood glucose of individuals with type 1 diabetes [1]- [3] . Various approaches to realizing such a system have been adopted, including techniques based upon polymer-encapsulated islets (a so-called bioartificial AP; [2] , [4] ), insulin-releasing polymers (a fully synthetic AP; [3] , [5] ), and the combined use of an insulin pump, glucose sensor and control algorithm (an electromechanical AP; [1] , [6] ). Currently, owing to the advent of reliable glucose sensors that operate continuously in the subcutaneous space, the electromechanical approach employing the subcutaneous route for both glucose sensing and insulin delivery is considered most promising for widespread clinical use [1] - [3] , [7] . Indeed, a considerable number of studies have demonstrated safety and effectiveness of such AP systems both in the clinical research center (CRC) and the outpatient environment [7] - [10] . However, while there is now little doubt that such AP systems are technically feasible, it remains less clear that they will be widely adopted by the patients [11] - [13] . So far a number of factors have been reported which may hinder widespread future adoption of such an AP [13] - [15] . Of these, a critically important factor appears to be the size of the AP. For example, a recent survey-based study ascertained the expectations of diabetes patients and parents of children with diabetes with regard to the potential future use of an AP and found 'small size' and 'discreet appearance', followed by 'being effective', as the most favored attributes of an AP [15] . In addition, many participants in this survey expect the future AP to be an all-in-one device that is similar in size to an insulin pump [15] . Unfortunately, current clinically tested AP systems fall short in meeting these expectations. They all require the patient to wear one to two pumps, each with an infusion cannula inserted into the patient's subcutaneous tissue, and one to two needle-type sensors with sensor tips inserted at separate subcutaneous tissue sites. Therefore, in order to broaden the appeal of the AP and increase the likelihood of achieving high adoption rates, it is desirable to integrate all components of the AP into one unit and reduce its size to approximately the size of a current insulin pump.
In pursuit of a simpler and more convenient treatment method for diabetes patients, we recently evaluated the possibility of using the site of subcutaneous insulin administration for the measurement of glucose [16] - [18] . We observed that glucose concentrations measured at the site of subcutaneous insulin infusion closely reflect plasma glucose levels. This finding suggests that glucose sensing and insulin delivery may be combined and simultaneously performed at a single adipose tissue site. Such a combining of glucose sensing and insulin infusion at a single tissue site, termed single-port treatment approach [17] , would allow a drastic reduction in the size of an AP system, because both the sensing and delivery components can be fully integrated into one design, which in turn could increase patient convenience and enhance acceptance of diabetes treatment with an AP. Following these proof-of-concept studies, we focused on the development of a treatment device that combines continuous glucose sensing and insulin delivery at the same tissue site (single-port device). Employing commercially available continuous glucose sensors and insulin infusion cannulas, several prototypic single-port devices with different sensor/cannula configurations were created [19] , [20] . Subsequent in vitro and in vivo investigations have shown that the most suitable configuration of glucose sensor and infusion cannula is the one where a Dexcom sensor is placed into the lumen of a Medtronic infusion cannula and positioned so that the glucose sensitive part of the sensor extends beyond the cannula end ( Fig. 1 ; [20] ). This developed single-port device can be easily assembled and the device's cannula-sensor unit be inserted into the tissue without modification of its commercially available constituent parts. Furthermore, the device can be connected to a conventional insulin pump and used to perform glucose sensing and insulin delivery in an open-loop manner ( Fig. 1) . Moreover, the device may also be used in combination with an algorithm to perform closed-loop glucose control (single-port AP; Fig. 2 ).
The objectives of the present study were to ascertain the accuracy of the glucose sensing with the single-port device and to assess the feasibility of the single-port device, when combined with an algorithm, to automatically control the blood glucose in diabetes patients.
II. MATERIALS AND METHODS

A. Study Subjects
Ten subjects were included in the study. They were of both sexes, in the age group of 18-65 years and diagnosed with type 1 diabetes. They had to have HbA1C values of <10%, and had to be treated with continuous subcutaneous insulin infusion. Subjects were excluded if they had evidence of clinically overt diabetic complications, or had plasma C-peptide levels >30 pmol/L. Each subject signed a written consent form prior to any study-related procedures. The study was approved by the ethics committee of the Medical University of Graz and the Austrian Agency for Health and Food Safety (Clinical Trials registration no. NCT02359617).
B. Study Protocol
Eligible subjects were studied over a period of up to 7 days. On study day 1, subjects were admitted to the CRC in the morning at 0800. Upon arrival, the single-port device was assembled in a laminar flow under sterile conditions and the sensor-cannula unit of the single-port device placed into the subject's subcutaneous tissue by the same two investigators (M.T., W.R.) in a standardized fashion. A detailed description of the assembling and insertion of the device as well as its first use in type 1 diabetes subjects can be found in [20] . Briefly, after removing the insertion needle from the cannula of an insulin infusion set (cannula length: 6 mm, tube length: 610 mm, SOF-Set Micro QR; Medtronic MiniMed, Northridge, CA, USA) ( Fig. 1b) , the housing of a continuous glucose sensor (Dexcom G4 Platinum Sensor; Dexcom Inc., San Diego, CA, USA) ( Fig. 1a ) was mounted onto the top of the infusion set's cannula housing using a transition piece (CNC-machined from polycarbonate; 4A engineering GmbH, Traboch, Austria) ( Fig. 1c,d ). Subsequently, the introducer needle of the sensor applicator, containing the enzyme-tipped sensor, was inserted through the self-sealing septum layer of the cannula housing, and then disposed in the lumen of the cannula so that the needle tip extended approximately 6 mm from the end of the cannula (Fig. 1e ). Before disposing the introducer needle into the cannula, the tube and cannula of the infusion set were filled with insulin (100 U/ml, Aspart; Novo Nordisk, Bagsvaerd, Denmark) using an insulin pump (Animas-Vibe Insulin Pump; Animas Corp., West Chester, PA, USA) attached to the tube ( Fig. 1d ). As the used infusion cannula from Medtronic exactly fits the introducer needle of the sensor applicator from Dexcom ( Fig. 1e ), it was possible to use the applicator to simultaneously insert cannula and sensor into the subcutaneous tissue of the subjects. Following insertion into the tissue, the introducer needle was withdrawn from the tissue by pulling up the collar of the applicator, thereby leaving both sensor and cannula of the single-port device inside the subcutaneous tissue with the glucose-sensitive sensor portion extending 6 mm beyond the cannula end ( Fig. 1f ). Afterwards, the arrangement was fixed to the skin using a hypoallergenic adhesive tape (i.e., the one included in the SOF-Set Micro QR; Medtronic MiniMed, Northridge, CA, USA) ( Fig. 1d ). Following fixation to the skin, a Dexcom sensor (G4 Platinum Sensor; Dexcom Inc., San Diego, CA, USA) was placed into the subcutaneous abdominal tissue at a distance >100 mm from the single-port device and used as a control sensor. Afterwards, the Animas pump connected to the single-port device ( Fig. 1d ) was programmed with the same basal insulin infusion profile that had been used by the subject prior to the study period. The subject's own insulin pump was then removed and the insulin infusion via the single-port device started. Subsequently, transmitters (G4 Transmitter Kit; Dexcom Inc.) were attached to the Fig. 1 . Single-port device: The device consists of a commercial glucose sensor from Dexcom (Dexcom G4 Platinum Sensor; Dexcom Inc., San Diego, CA, USA) (a), a commercial insulin infusion cannula from Medtronic (cannula length: 6 mm, tube length: 610 mm, SOF-Set Micro QR; Medtronic MiniMed, Northridge, CA, USA) (b), and a custom-made transition piece (CNC-machined from polycarbonate; 4A engineering GmbH, Traboch, Austria) (c). Since the applied infusion cannula from Medtronic exactly fits the introducer needle of the sensor applicator from Dexcom (e), it is possible to use the applicator to simultaneously insert cannula and sensor into the subcutaneous tissue of the subjects. When inserted, the glucose-sensitive sensor portion extends about 6 mm beyond the cannula end (f). Following insertion, the sensor is connected with a transmitter from Dexcom and the infusion cannula connected to an insulin pump from Animas via an infusion set tube from Medtronic (d). The pump delivers the insulin and displays the measured glucose values. single-port and control sensor. To display and store the sensor readings, the transmitter connected to the single-port sensor was paired to the receiver on the Animas pump ( Fig. 1d ), and the transmitter attached to the control sensor was paired with a handheld receiver (G4 Receiver Kit-mg/dl; Dexcom Inc.). Following a 2-h run-in period, both sensors were calibrated and the continuous glucose monitoring started. Calibration of the sensors was performed using capillary blood glucose measurements obtained with a blood glucose meter (FreeStyle Freedom Lite; Abbott Diabetes Care, Alameda, CA, USA). During the sensor run-in period, the subjects were trained in handling of the treatment devices. At ∼1230, the subjects received a standard meal (60g carbohydrates). Shortly before the meal, an insulin bolus was administered via the infusion cannula of the single-port device using the Animas pump. The size of the insulin bolus administered was calculated using medical records on each subject's insulin-to-carbohydrate ratio. At ∼1400, the subjects were allowed to leave the CRC. In the evening of study day 1 and during study day 2, the subjects were encouraged to continue their usual activities in their home/work environment and continue with their usual diabetes treatment, but to use the single-port device to administer insulin. In addition, they were asked to perform at least 7 blood glucose measurements per day using the Abbott glucose meter and to keep a written diary containing the estimated carbohydrate intake, the insulin bolus amounts, results of the blood glucose measurements as well as the time of meals, bolus administrations, and glucose measurements. To utilize the single-port device (b) for closed-loop insulin delivery, it was connected to the AP@Home closed-loop platform. This platform is comprised of a control unit (App-1 Unit; Triteq, Hungerford, UK) running a model predictive control (MPC)-based algorithm (Cambridge University Algorithm; University of Cambridge, Cambridge, UK) (e) and a data acquisition and processing software running on a laptop pc. The control unit is capable of receiving the glucose readings from a Dexcom receiver kit (d), and controlling the insulin infusion rate of an insulin pump from Roche (Accu-Chek Spirit Combo; Roche Diabetes Care, Burgdorf, Switzerland) (c). On the closed-loop study day at the CRC, the Animas pump, which was previously used for open-loop insulin delivery, was replaced by the insulin pump from Roche (b-c), and the Dexcom receiver (d) was set to receive the glucose readings from the transmitter attached to the single-port device sensor (a, b). Based on the glucose readings received from the single-port device, the control unit determined the basal insulin infusion rates and set them automatically on the Roche pump (c-e). Insulin boli were administered manually prior to each meal. Each time, the information of the bolus dose, the time of the bolus delivery, the time of the meal ingestion, and the carbohydrate content of the meal was provided to the control unit running the algorithm. Additionally, the control unit was initialized with the subject's weight, age, total insulin dose, and the basal insulin infusion profile previously used by the subject.
On study day 3, at ∼0700, the subjects were admitted to the CRC for performing closed-loop insulin delivery. Upon arrival, a catheter (20-gauge, Vasofix R Safety; B. Braun, Melsungen, Germany) was inserted into a vein of the subject's forearm for blood sampling. The forearm with the sampling catheter was then placed under a heating blanked (P10; Beurer GmbH, Ulm, Germany) and maintained at ∼55°C to ensure arterialization of the venous blood. Blood samples were taken every 10-30 min during day time and every 20-60 min during night. To assure consistency in the performance comparison between the singleport device and control sensor, finger capillary punctures were additionally performed for determining the blood glucose concentrations using the Abbott glucose meter. After insertion of the blood sampling catheter, the AP@Home closed-loop platform was connected to the single-port device as described in Fig. 2 . Closed-loop glucose control was then commenced at 0930 and continued until the morning of the next day. During the study day, the subjects were given breakfast (50g carbohydrates) at 1000, lunch (60g carbohydrates) at 1300, snack (20g carbohydrates) at 1600, and dinner (80g carbohydrates) at 2000. An insulin bolus was administered manually via the single-port device cannula before each meal, with the exception of the snack at 1600, where insulin was delivered automatically. In the afternoon, the subjects were encouraged to mimic their usual day such as to work on a computer, watch television or to walk inside the hospital premises. On the next morning, at 0730, a breakfast (50g carbohydrates) was given accompanied by a manually administered prandial insulin bolus. Following breakfast, the closed-loop platform was disconnected and the Animas pump reconnected to the single-port device. Afterwards, the subjects were allowed to go home. On the study days 4 to 7, the subjects continued with the use of the single-port device in their home/work environment. In addition, subjects were asked to report daily whether they experienced an infection at the sensor/cannula insertion site, whether they experienced uncorrectable hyperglycemia or whether they observed a significant difference between the amount of administered insulin and the amount of insulin usually needed to keep their blood glucose concentration normal. After study day 7, or when an insertion site infection or a blood glucose deterioration occurred, or when a significant increase in the amount of insulin above the amount usually needed was observed, the subjects removed the singleport device and continued the treatment using their own insulin pump. The subjects were asked to come to the CRC on the subsequent day, where all study-related equipment was collected and a final physical examination performed.
C. Analytical Procedures
The plasma glucose concentrations were measured at the CRC by the glucose oxidase method on a bench-top laboratory analyzer (Super GL 2; Dr. Müller Gerätebau GmbH, Freital, Germany) with a coefficient of variation of <2%. In order to maintain the function of the single-port device sensor during insulin bolus delivery (see Fig. S1 in the Online Supplementary Material and [20] ), the insulin solution was spiked with small amounts of a 20%-glucose solution (20% Glucosteril; Fresenius Kabi, Bad Homburg, Germany) to obtain a glucose concentration of approximately 200 mg/dl. The plasma C-peptide concentrations were determined by a two-site sandwich chemiluminescent immunoassay using an ADVIA Centaur platform (Siemens AG, Erlangen, Germany) with a lower limit of quantification of 20 pmol/L. HbA1C was measured by high-performance liquid chromatography (HA-8160; Menarini Diagnostics, Florence, Italy).
D. Data Analysis
The agreement between the glucose concentrations obtained with single-port device and control sensor and that determined with the glucose meter from Abbott was assessed for each subject by using the median and mean ARD, as well as the precision absolute relative difference (PARD) and applying the correlation and error grid analysis and the method of residuals [21] - [24] . The median ARD (medARD) and mean ARD (MARD) were calculated as the average (median or mean) of the absolute value of the percentage difference between each paired sensor and glucose meter reading, with the glucose meter reading as the reference. Correlation analysis was performed using Pearson's product-momentum correlation coefficient (CC). The PARD was calculated as the mean (or median) of the absolute value of the percentage difference between a single-port device sensor reading and the time-matched control sensor reading, with the mean of the two sensor readings as the reference [24] . When calculating the MARD, medARD and CC only a small portion of the glucose sensor data was used (i.e., the sensor readings for which corresponding blood glucose meter readings were available). In order to examine if this portion of sensor data used to calculate such agreement indexes was representative for the whole set of sensor data, PARD values were calculated for those sensor readings for which corresponding blood glucose meter readings were obtained (PARD REF ) and for those for which no corresponding blood glucose readings were available (PARD noREF ). To assess the feasibility of closedloop insulin delivery with the single-port device, the proportion of time, that the glucose level-as measured by the singleport device sensor-is in the target range of 3.9-10.0 mmol/L (TTR), was determined both for the closed-loop insulin delivery period at the CRC and for the open-loop insulin delivery period in the patients' home environment. To determine the accuracy and precision of the glucose meter used by the patients for performing capillary blood glucose measurements (Abbott FreeStyle Freedom Lite), venous blood samples (n = 69) were additionally analyzed on the glucose meter, and the results were compared with plasma glucose concentrations obtained with the laboratory instrument used at the CRC. The MARD, medARD, residual mean and residual 2SD values obtained for the glucose meter were 5.1%, 4.0%, −3.3%, and 11.8%, respectively.
The ARD, CC, PARD and TTR data as well as the agreement index data obtained from the application of the method of residuals and error grid analysis were examined with the Wilcoxon´s signed-rank test and the paired Student's t test. A P value below 0.05 was considered to indicate statistical significance. The analysis of the data was performed using an OriginLab software package (Version 8.5; OriginLab Corp. Northampton, MA, USA).
III. RESULTS
A. Subject Characteristics
Eleven subjects were invited to take part in the study. One patient was excluded due to a screening error (HbA1C >10%). The ten subjects completing the study (3 females and 7 males) had an average age of 32.8 ± 10.9 years (mean ± SD; range 21-54 years) and an average BMI of 25. Results of applying the method of residuals. Percentage differences between sensor readings and capillary blood glucose measurements (residuals, y-axis) are plotted against capillary blood glucose measurements (x-axis). Short dashed line represents the residual mean, and long dashed lines represent the residual mean plus minus 2 times the residual SD. The mean differences for the single-port device sensor (c) and the control sensor (d) were 3.14% and −1.08%, respectively. The 2SD values for the single-port device sensor (c) and the control sensor (d) were 39.0% and 38.8%, respectively.
B. Insertion and Wear Time of the Single-Port Device
The time taken to perform the assembling and subcutaneous insertion of the single-port device was 15-20 min. Insertion of the single-port device was successful on the first attempt in each of the ten subjects. Similarly, there were no failed attempts at inserting the control sensor. Furthermore, after inserting the single-port device and control sensor, in no one of the subjects did any sensor failure occur. Five of the ten studied subjects wore the single-port device for the full seven days, another four for six days, and one subject wore the device for five days. Overall, the mean wear time of the device was 6.4 days. The reason for study termination prior to day 7 was, in each case, the increase in the amount of insulin above the amount usually needed to keep the blood glucose concentration normal.
C. Glucose Monitoring With the Single-Port Device
The glucose concentration time courses obtained with the single-port sensor paralleled those measured with the control sensor. In addition, the glucose concentrations obtained with the two sensors agreed well with the blood glucose levels determined with the blood glucose meter. Time courses of the sensor and blood glucose concentration as well as insulin infusion rate from a representative subject are shown in Fig. 3 (data for all subjects are given in Fig. S2 of the Online Supplementary Material). For each, the single-port device sensor as well as the control sensor, 632 paired sensor and blood glucose values were obtained from the experiments. Error grid and residual plots for all collected data pairs are shown in Fig. 4a,b and Fig. 4c,d . Agreement indexes obtained for each individual subject from the application of the error grid analysis and method of residuals are given in Supplementary Tables S1 and  S2 . Error grid analysis indicated that the average percentage number of sensor readings that fall into the clinically acceptable range (zones A and B) is high for the single-port device (median: 98.2%; interquartile range: 97.7-98.9%) and comparable to that obtained for the control sensor (vs. 97.6%; 96.4-98.8%; P = 0.063 with Wilcoxon signed rank test). Furthermore, applying the method of residuals, the average residual 2 SD obtained for the single-port device (37.3%; 29.2-47.2%) was similar to that calculated for the control sensor (vs. 38.5%; 34.2-40.7%; P = 0.695 with Wilcoxon signed rank test). The ARD and CC values obtained for the single-port device and control sensor of each subject are given in Supplementary Table S3 .
The average medARD obtained for the single-port device was found to be low (8.9%; 7.3-11.3%; n = 10) and did not differ from that for the control sensor (vs. 9.8%; 8.9-11.5%; P = 0.232 with Wilcoxon signed rank test). Similarly, the average MARD calculated for the single-port device (13.0%; 10.5-16.7%) was comparable to that of the control sensor (vs. 13.9%; 11.9-15.3%; P = 0.922 with Wilcoxon signed rank test). Furthermore, there was no difference between the average CC calculated for the single-port device (0.94; 0.91-0.95) and that calculated for the control sensor (vs. 0.92; 0.91-0.95; P = 0.322 with Wilcoxon signed rank test). The PARD values obtained for the sensor data of each subject are given in Supplementary Table S4 . The average median PARD calculated for the sensor readings for which corresponding glucose meter readings were obtained (11.2%; 10.0-12.4%; n = 10) did not differ from that calculated for the sensor readings for which no corresponding glucose meter readings were available (vs. 11.3%; 9.4-12.5%; P = 0.695 with Wilcoxon signed rank test). Similarly, the average mean PARD obtained for the sensor readings for which corresponding meter readings were available (16.0%; 13.7-16.6%) was comparable to that calculated for the sensor readings for which no corresponding meter readings were obtained (vs. 14.5%; 13.3-16.5%; P = 0.846 with Wilcoxon signed rank test).
D. Closed-Loop and Open-Loop Insulin Delivery With the Single-Port Device
Insulin delivery with the single-port device was found to be reliable during both the closed-loop glucose control period at the CRC and the treatment period in the patients' home/working environment. No cannula occlusion, cannula dislodgement or insulin leakage was observed in any of the subjects. The average time courses of the glucose concentration and the insulin delivery rate observed during closed-loop glucose control period are shown in Fig. 5 . As can be seen, the closed-loop insulin delivery, using the single-port device in combination with the AP@home platform, was adequate to achieve and maintain near normoglycemia during the study day. The TTR values obtained for each subject are given in supplementary Table S5 . The average TTR was found to be significantly higher during the closedloop glucose control period (70.4%; 58.1-87.3%) than during the home phase of the study (vs. 54.8%; 45.9-61.0%; P = 0.002 with Wilcoxon signed rank test). 
IV. DISCUSSION
The present study was designed to evaluate a novel treatment device that combines glucose sensing and insulin delivery at the same adipose tissue site (single-port device). The quality of the glucose sensing with the single-port device was found to be comparable to that with the control sensor both during the treatment period in the patients' home environment and the closed-loop glucose control period at the CRC. Furthermore, the insulin delivery with the single-port device was found to be reliable and safe during home use and, when performed in combination with the control algorithm, was adequate to achieve and maintain near normoglycemia. Taken together, these findings indicate that the performance of insulin delivery and glucose sensing at the same tissue site using the single-port device did not adversely affect the functioning of the device's constituent components. Therefore, combining insulin delivery and glucose sensing at the same tissue site may be a viable approach to reduce the size of an AP system.
During the open-loop treatment period at the patients' home, the single-port device was attached to the Animas pump integrating a Dexcom sensor receiver which enabled it to be wirelessly connected to the single-port glucose sensor and to display and store the glucose readings received from the sensor (Fig. 1) . However, to provide real-time insulin dosing decisions based on the received glucose readings, there would need to be an AP control algorithm implemented additionally into the insulin pump. Unfortunately, there is currently no insulin pump from Animas available that is integrated with an AP control algorithm. Advantageously, the combined integration of a control algorithm and wireless connectivity into an insulin pump, like the Animas pump, should not pose any technological obstacles nor increase the size of the insulin pump. Therefore, combining the single-port device with an insulin pump that houses both wireless connectivity and a control algorithm may lead to the commercial introduction of an AP device that readily fulfills the expectations of diabetes patients with regard to its shape (i.e., all-in-one device) and size (i.e., similar to an insulin pump) [15] .
In order to perform closed-loop glucose control in the present study, the single-port device was connected to the Roche insulin pump, which wirelessly communicated with the standalone Tritec control unit housing the Cambridge University Algorithm (Fig. 2) . Based on the insulin dosing instructions sent by the control unit, the Roche insulin pump automatically adjusted the insulin delivery into the subcutaneous tissue. During the 24-h of closed-loop glucose control, the glucose levels of the patients were maintained within the target range of 3.9-10.0 mmol/L for a median of 70% of the time. In comparison, during the open-loop treatment period at home, the patients' glucose levels were within the target range for a medium of 55% of the time. This improvement in glycemic control achieved with the singleport AP is similar to that previously obtained with dual-port AP systems also using the Cambridge University Algorithm [10] , [25] - [27] or other MPC-based algorithms [28] , thereby indicating that the combining of insulin delivery and glucose sensing at the same tissue site may not compromise the AP's effectiveness in controlling patients' blood glucose levels.
In order to assess the precision and accuracy of the Dexcom control sensor and the Dexcom sensor used in the single-port device, several agreement indexes, such as the MARD and the residual 2 SD, were calculated for each sensor (Supplementary Tables S1-S3). Values of the agreement indexes obtained for the single-port device sensor were similar to those obtained for the control sensor, which was worn at least 100 mm away from the single-port device and, thus, was most likely not affected by the infused insulin. Furthermore, the PARD value calculated for the sensor readings for which corresponding glucose meter readings were obtained was comparable to that calculated for the sensor readings for which no corresponding glucose meter readings were available ( Supplementary Table S4 ), thereby suggesting that the portion of the sensor data used to calculate the agreement indexes was representative for the whole set of sensor data. In addition, the obtained values of the agreement indexes were comparable to those recently reported for the same commercially available generation of Dexcom sensors (i.e., G4 Platinum sensor; [29] - [32] ). For example, studies assessing the accuracy of this generation of Dexcom sensors have observed average MARD values (range: 11-14%; [29] , [31] , [32] ) that are similar to those obtained for the control and single-port device sensor in the present study (13.9 and 13.0%, respectively). Overall, these data indicate that continuous glucose monitoring with sensors placed at the site of subcutaneous insulin delivery is feasible and its quality is comparable to that of continuous glucose monitoring with sensors placed in insulin-unexposed subcutaneous tissue.
The Dexcom G4 sensor and the Medtronic SOF-Set infusion cannula employed in the single-port device differ considerably in their approved or recommended usage duration. Whereas the Dexcom G4 sensor is approved for 7 days of continuous use [29] - [32] , the Medtronic SOF-Set infusion cannula, like other commercial insulin infusion cannulas, is recommended to be replaced every 2-3 days [33]- [35] . It is well known that prolonged use of an insulin infusion cannula beyond the recommended 2-3 day period increases the risk for infection, scarring and lipodystrophy at the infusion site as well as deterioration of the blood glucose control due to reduced insulin absorption [33] - [35] . Therefore, during the open-loop treatment period at home, the subjects were instructed to stop using the single-port device when there were signs of infection at the sensor/cannula insertion site, when correction boli failed to decrease the glucose levels, or when there was an increase in the amount of insulin above the amount usually needed to keep the glucose concentration normal. Owing to the occurrence of increases in the insulin amount above the amount usually needed, half of the studied subjects prematurely discontinued the device use-four subjects after 6 days and one after 5 days. However, the other half of the subjects wore the device for the full 7 days, as no insertion site infection, or uncorrectable hyperglycemia, or increase in the insulin amount occurred in any of these subjects. Overall, the mean wear time of the single-port device was 6.4 days. These findings indicate that, in a large group of diabetes patients, the use of the single-port device may be safely prolonged beyond the 2-3 day period recommended for the use of insulin infusion sets. This conclusion is consistent with recent findings of Patel et al. [36] , who assessed the effect of duration of use on infusion set function in diabetes patients. The authors observed that infusion sets were intact and properly functioning up to a median usage duration of 6.06 days.
Currently, a number of academic and industrial research groups are pursuing alternative approaches to realize a singleport treatment system, including techniques based upon the integration of an electrochemical glucose sensor [37] , [38] , an optical glucose sensor [39] , or a glucose-responsive hydrogel [40] onto the outer wall of an insulin infusion cannula. For the insertion of these sensor-cannula arrangements, it may be important to protect the sensor portion against intrusion forces generated during the insertion process. Consequently, as opposed to our approach where the sensor is protected by the insertion needle ( Fig. 1e ), the alternative approaches may require substantial modifications to the conventional sensor deposition techniques, infusion cannulas, and/or insertion procedures, thereby increasing development and manufacturing costs.
Limitations of our study include the lack of a closed-loop control arm in which a conventional dual-port AP system is used to control the patients' blood glucose levels in the CRC setting. Thus, a future parallel-arm study applying both the single-port and dual-port AP system will be needed to determine whether the performance of the single-port AP is equivalent to that of a dual-port AP. Since the improvement in glycemic control achieved with the single-port AP was comparable to that previously obtained with conventional dual-port AP systems, we anticipate that no difference in the performance of the two AP systems will be observed in such a study. Another limitation of our study may be that the glucose sensing accuracy of the single-port device and control sensor was evaluated against blood glucose meter instead of laboratory instrument readings. Generally, glucose meters have a lower level of accuracy than laboratory instruments and, thus, when comparisons are made between continuous glucose sensors and glucose meters, the limited accuracy of the glucose meters can influence the estimated accuracy of the glucose sensor (e.g., it may increase the MARD value of the sensor [41] ). The glucose meter used in the current study (Abbott FreeStyle Freedom Lite) was previously found to be one of the most accurate glucose test strip devices available [42] , [43] . Thus, because of the relatively high level of accuracy of the used glucose meter (e.g., the MARD value determined for this meter is about 5%, see Section II or [43] ), the impact on the estimated accuracy of the glucose sensing with the single-port device and control sensor may have been minimal [41] . Finally, the current study is a single-center study of a limited number of participants and, as such, provides only initial evidence that the quality and reliability of the glucose sensing and insulin infusion with the single-port device are equivalent to that with commercial stand-alone glucose monitoring and insulin delivery devices. Thus, in order to collect definitive evidence for equivalent performance, a future confirmatory study in a much larger sample size will be needed.
V. CONCLUSION
The results of the present study indicate the feasibility of open-and closed-loop glucose control in diabetes patients using a treatment device that combines glucose sensing and insulin delivery at the same tissue site. The reduction in device size and invasiveness achieved by this design may largely increase patient convenience and enhance acceptance of diabetes treatment with continuous glucose monitoring and insulin delivery technology.
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